Dr. Reddy’s reported robust Q2FY23 numbers

Posted by : Sheen Hitaishi | Wed Nov 09 2022

Dr. Reddy’s reported robust Q2FY23 numbers

Dr. Reddy’s Laboratories Ltd is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars, and proprietary products. It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility, and several R&D centres across the globe. The company on 28th October 2022 announced better than expected Q2FY23 numbers and has a market capital of Rs 74,233 crores. During Q2FY23, the company saw healthy growth across different segments, mainly driven by growth in the US market due to favourable currency impact and new launches. Post the results, brokerages have upgraded their rating on the stock after making a positive stance for the future prospects of the company. So, let’s now understand their Q2FY23 numbers in deeper detail and look for the possible investment opportunity in this healthcare stock.

Dr. Reddy’s results Q2FY23: Massive YoY growth in Europe business drove healthy performance

Dr. Reddy’s during Q2FY23 reported better-than-expected 12% YoY growth in consolidated net profit at Rs 1,113 crores against Rs 992 crores reported in Q2FY22. While the company saw a marginal fall of 6.3% QoQ in PAT from Rs 1,189 crores reported in Q1FY23.

Whereas the company also reported a 9% YoY increase in consolidated revenue at Rs 6,306 crores against revenue of Rs 5,763 crores in Q2FY22. Sequentially, consolidated revenue grew by 21% from Rs 5,233 crores in Q1FY23.

Dr.Reddy revenue growth

“We are pleased with the strong financial performance in the current quarter, driven by the launch of Lenalidomide capsules in the US market”, said GV Prasad, Co-Chairman and Managing Director.

Further, North America continues to be the largest contributor to the company’s revenues with a 44% share and was followed by emerging markets (19% share), India (18% share), PSAI (10%), Europe at 7% and others at 1% of the total revenue.

Dr. Reddy growth

The company generated Rs 2,800 crore of its revenue from North America, with a YoY growth of 48% and a growth of 57% in the quarter. While the revenue from the Emerging Markets at Rs 1,225 crores was down 6% YoY but up 36% QoQ. Within Emerging markets, the sequential growth was driven by 85% growth in Russia and was primarily due to a lower sales base of Q1FY23. The rest of the world witnessed a sequential growth of 6%, driven by new product launches, partly offset by a reduction in base volumes and sales price of some of our products.

You may also like: 

Dr. Reddy’s results Q2FY23: Highest EBITDA along with highest margin % at 30%

The gross margins for Q2FY23 were at 59.1% which was 570 basis points higher than 53.4% a year ago. The gross margin in Q1FY23 stood at 49.9%. They were mainly driven by product mix (including new products), and accruals related to the production-linked incentive scheme, which was partly offset by price erosion and provision made on inventory for Covid products.

Further, EBITDA margins grew 649 bps YoY to 30%. While absolute EBITDA came in at Rs 1,899 crores in Q2FY23, up 40% YoY from Rs 1,360 crores in Q2FY22 and 101% QoQ from Rs 941 crores in Q1FY23.

Lastly, the company incurred a CapEx of Rs 250 crore during the quarter.

Dr.Reddy's Growth

Univest View along with Technical Analysis:

Dr. Reddy in Q2FY23 reported strong performance on the back of new launches during the quarter, especially gRevlimid. As a result, the company has exceeded analysts’ expectations for the quarter on the profitability front. On the revenue side, the US sales saw robust growth, while few regions were impacted due to last year’s high base. Further, the company will actively look for new investment avenues for growth across all the business segments. Therefore, margins are to see some pressure due to increased R&D and marketing activities and investment in biosimilar & injectable product pipelines.

While coming onto technical analysis, Dr. Reddy’s stock can be moving in a sideways trend with a 50 EMA line above 100 EMA but below the 200 EMA line. At the start of 2022, the company experienced a steep correction but with their margin pressure bottoming out in Q1FY23, the situation seems favourable now. Post the announcement of Q2FY23 results the company’s share price was seen making a small up move. While the brokerages have upgraded their ratings for the company, the share price is expected to break from its July peak, as it continues to take support at 4066.

ABOUT THE AUTHOR

Ketan Sonalkar (SEBI Rgn No INA000011255

Ketan Sonalkar is a certified SEBI registered investment advisor and head of research at Univest. He is one of the finest financial trainers, with a track record of having trained more than 2000 people in offline and online models. He serves as a consultant advisor to leading fintech and financial data firms. He has over 15 years of working experience in the finance field. He runs Advisory Services for Direct Equities and Personal Finance Transformation.

Note – This channel is for educational and training purpose only & any stock mentioned here should not be taken as a tip/recommendation/advice

You may also like: Sun Pharma results

icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .
 
Univest Stock Broking Disclosures
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
1. 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
2. On an average, loss makers registered net trading loss close to ₹ 50,000
3. Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
4. Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Univest Stock Broking Private Limited and offering such services, please send us an email at hello@unibrokers.in
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number. Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL every month.
Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the- indian-securities-market_74794.html. ODR portal for Investors - https://smartodr.in/login.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
General
arrow down